D-Dimer Test Flags Clot Risk, Aids Broader Diagnosis
D-Dimer test is not specific to any disease and thus is performed in conjunction with other evaluations and diagnostic tests. 0.5 is measured as normal range for D-dimer and greater than 0.5 is measured to be positive. D-dimer decreases under abnormal medical case which is measured by specific antibodies.
Key Growth Drivers and Opportunities
Demand for D-Dimer Testing: Traditional testing is replaced by D-dimer testing, allowing for faster test results, quicker diagnosis, shorter patient wait times, and better patient outcomes overall. D-Dimer testing to be more widely used by customers offering compelling advantages. Moreover, the growing prevalence of lung and cardiovascular illnesses might, in extreme circumstances, lead to potentially fatal blood clot problems, which propels D-Dimer Test.
Rising Genetic Disorders: Increasing cases of Thrombus embolism along with various cardiovascular and pulmonary diseases that could be life threating due to clot formation increases the demand for D-Dimer Test globally. D-dimer functions as valuable marker in various clinical conditions such as HIV, atrial fibrillation, coronary artery disease. New technological advancement such as development of aptamers, reducing use of antibodies for D-dimer testing being cost-effective, long-lasting boosts D-Dimer Test widening scope for these tests.
Challenges
The major challenge consists of inadequate skilled professionals and trained professionals unable to perform the test properly and lack of knowledge leads to false results and restrains the D-Dimer test Market. High cost and poor reimbursement policies restrains people to take such tests for proper diagnosis increasing the prevalence of disease and deaths.
Innovation and Expansion
Study Links Long COVID Brain Fog to Blood Microclots
In September 2023, Finding was published in Nature Medicine, suggesting links between brain fog in long COVID and 'micro clots' in the blood. These clots often contain misfolded fibrinogen proteins that prevent the clots from breaking down, and this effect can clog blood vessels and block oxygen flow to the brain and other organs.
Blood tests for both D-dimer and fibrinogen are already standard around the world, so researchers had plenty of available data to check whether the same phenomenon occurred in other groups of patients.
LumiraDx Expands Rapid Testing for VTE and Heart Failure
In June 2022, LumiraDx Limited, a next-generation point of care Diagnostics Company, announced its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism (VTE) in symptomatic patients.
With these two additions, the LumiraDx Platform can further support clinicians in quickly and accurately assessing patient symptoms for both VTE and heart failure at the point of care. The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay for the quantitative measurement of NT-proBNP in human capillary, venous whole blood and plasma specimens.
Inventive Sparks, Expanding Markets
The major companies present in the D-dimer test market are Bio/Data Corporation, Becton Dickinson BV, Sysmex Corporation, Abbott Laboratories, Inc., Dickinson and Company, Hoffman-La Roche Ltd., among others. Global companies work to foster lasting innovation, grow their markets, and provide quality goods and services. They concentrate on improving customer experience, applying tech, and creating strong operations.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
TIME BUSINESS NEWS
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
3 hours ago
- Time Business News
D-Dimer Test Flags Clot Risk, Aids Broader Diagnosis
D Dimer Test is a kind of blood test detecting the presence of D-dimer in the blood. D-dimer is a protein fragment of fibrin formed after Fibrinolysis degradation of blood clot. It is helpful to diagnose the conditions with abnormal blood clots formation and breakdown, intravascular fibrinolysis, and coagulation. High D-dimer levels indicate clinical suspicion of a blood clot and needs ultrasound, CT angiography, scans could be performed to confirm the presence of clot and location of clot. D-Dimer test is not specific to any disease. D-Dimer test is not specific to any disease and thus is performed in conjunction with other evaluations and diagnostic tests. 0.5 is measured as normal range for D-dimer and greater than 0.5 is measured to be positive. D-dimer decreases under abnormal medical case which is measured by specific antibodies. Key Growth Drivers and Opportunities Demand for D-Dimer Testing: Traditional testing is replaced by D-dimer testing, allowing for faster test results, quicker diagnosis, shorter patient wait times, and better patient outcomes overall. D-Dimer testing to be more widely used by customers offering compelling advantages. Moreover, the growing prevalence of lung and cardiovascular illnesses might, in extreme circumstances, lead to potentially fatal blood clot problems, which propels D-Dimer Test. Rising Genetic Disorders: Increasing cases of Thrombus embolism along with various cardiovascular and pulmonary diseases that could be life threating due to clot formation increases the demand for D-Dimer Test globally. D-dimer functions as valuable marker in various clinical conditions such as HIV, atrial fibrillation, coronary artery disease. New technological advancement such as development of aptamers, reducing use of antibodies for D-dimer testing being cost-effective, long-lasting boosts D-Dimer Test widening scope for these tests. Challenges The major challenge consists of inadequate skilled professionals and trained professionals unable to perform the test properly and lack of knowledge leads to false results and restrains the D-Dimer test Market. High cost and poor reimbursement policies restrains people to take such tests for proper diagnosis increasing the prevalence of disease and deaths. Innovation and Expansion Study Links Long COVID Brain Fog to Blood Microclots In September 2023, Finding was published in Nature Medicine, suggesting links between brain fog in long COVID and 'micro clots' in the blood. These clots often contain misfolded fibrinogen proteins that prevent the clots from breaking down, and this effect can clog blood vessels and block oxygen flow to the brain and other organs. Blood tests for both D-dimer and fibrinogen are already standard around the world, so researchers had plenty of available data to check whether the same phenomenon occurred in other groups of patients. LumiraDx Expands Rapid Testing for VTE and Heart Failure In June 2022, LumiraDx Limited, a next-generation point of care Diagnostics Company, announced its cardiovascular offering with a CE Mark for its new NT-proBNP test to aid in the diagnosis of CHF and an updated CE Mark for its D-Dimer test to now rule out venous thromboembolism (VTE) in symptomatic patients. With these two additions, the LumiraDx Platform can further support clinicians in quickly and accurately assessing patient symptoms for both VTE and heart failure at the point of care. The LumiraDx NT-proBNP test is a rapid microfluidic immunofluorescence assay for the quantitative measurement of NT-proBNP in human capillary, venous whole blood and plasma specimens. Inventive Sparks, Expanding Markets The major companies present in the D-dimer test market are Bio/Data Corporation, Becton Dickinson BV, Sysmex Corporation, Abbott Laboratories, Inc., Dickinson and Company, Hoffman-La Roche Ltd., among others. Global companies work to foster lasting innovation, grow their markets, and provide quality goods and services. They concentrate on improving customer experience, applying tech, and creating strong operations. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
USA Today
6 hours ago
- USA Today
Flesh-eating bacteria case in Cape Cod prompts public health alert: What to know
A warning from the Massachusetts Department of Public Health may have some beachgoers exercising a little more caution as they try to escape the August heat. Residents and visitors at Buzzards Bay, a community on the south end of Cape Cod, are on alert after officials identified a person with a rare, flesh-eating bacterial infection in the area. Officials said the bacteria, known as Vibrio, could pose a risk to others in nearby coastal waters. The Vibrio species, which includes Vibrio vulnificus, can cause severe and life-threatening infections. Some can lead to necrotizing fasciitis, which kills off flesh around an open wound. Many people with a Vibrio vulnificus infection can get seriously ill and need intensive care or limb amputation. About 1 in 5 people with this infection die, sometimes within a day or two of becoming ill. But it's not the first time this bug has made its way to the Massachusetts bay: In a news release, the department of health said there have been seven cases of the illness over the last seven years among residents of the commonwealth, including four who were exposed in Massachusetts. The Vibrio bacteria and the infection it causes are usually more common in warmer waters, including in the Gulf Coast states of Louisiana, Texas and Florida, Dr. Larry Madoff told USA TODAY. But it's increasingly being seen northeastern states along the Atlantic coast, he added, such as Massachusetts and New York. "It's associated with warmer waters, and our waters are getting warmer," said Madoff, adding that the area where it's been found, Buzzards Bay, is an area with estuaries, small islands and warmer water on the western area of Cape Cod. The Vibrio bacteria also thrive in salty and brackish waters along the Atlantic coast, said Madoff, medical director for the Massachusetts Department of Public Health's Bureau of Infectious Disease and Laboratory Sciences. Above-average water temperatures are creating the conditions that allow the bacteria to grow, especially in the spring, summer and early autumn. Still, he said, there's no need for most people to worry, as long as they take certain precautions. "I would not discourage people from going to the beach," he said. "The beach is good and people need to cool off." What precautions should people take against flesh-eating bacteria? There are several species of Vibrio bacteria that can cause people to fall seriously ill. So how can people protect themselves? The bacteria is opportunistic, and it can enter the body through open wounds, health officials said. Foods like contaminated shellfish can also carry the bacteria. People with health conditions including liver disease, cancer, diabetes, HIV or who are on immunosuppressants are at highest risk of severe illness from the bacteria following exposure. Some precautions include: What are some symptoms and signs of flesh-eating bacterial illness? According to the U.S. Centers for Disease Control and Prevention, common signs of a Vibrio infection include diarrhea, stomach cramps, nausea, vomiting, fever, chills, dangerously low blood pressure and blistering lesions. Wounds that become infected may be red, swollen or discolored and may have a discharge.
Yahoo
12 hours ago
- Yahoo
Abbott, Siemens Healthineers, and Thermo Fisher Scientific Lead the Market with Innovative Portfolios and Strategic Expansion
The HIV Diagnostics Companies Quadrant report offers an in-depth analysis of the global HIV diagnostics market, assessing over 100 companies and highlighting the Top 14 leaders. Market expansion is driven by rising HIV/AIDS prevalence, point-of-care technological advancements, and awareness campaigns. However, high costs and skilled technician shortages hinder growth. North America leads in market dominance due to its HIV/AIDS prevalence and advanced technologies, while Asia Pacific is projected to grow fastest. Key players like Abbott, Siemens Healthineers, and Thermo Fisher Scientific employ strategies like acquisitions and innovations to maintain strong market positions amid evolving trends. Dublin, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The "HIV Diagnostics - Company Evaluation Report, 2025" report has been added to HIV Diagnostics Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for HIV Diagnostics. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and emerging trends shaping the industry. 360 Quadrants evaluated over 100 companies, of which the Top 14 HIV Diagnostics Companies were categorized and recognized as the quadrant growth can be attributed to the rising prevalence of HIV/AIDS, the advantages offered by point-of-care instruments & kits, and increasing initiatives for HIV awareness campaigns. However, the high cost of NATs, operational barriers, and the shortage of skilled laboratory technicians are key factors restraining the market growth. The high growth potential of emerging economies and the trend of self-testing are expected to provide lucrative opportunities for market players during the forecast HIV diagnostics market is segmented into six regions: North America, Europe, the Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America dominated the global market in 2023. Factors such as the rising prevalence of HIV/AIDS, advancements in PoC instruments and kits, increasing awareness about HIV/AIDS, and increasing blood transfusion and blood donations are driving the growth of the HIV diagnostics market in North the Asia Pacific market is expected to grow at the highest CAGR during the forecast period. The high growth rate of the Asia Pacific market can be attributed to the rising target patient population; the expansion of emerging economies; the increasing availability of technologically advanced POC products; favorable government initiatives for HIV awareness; and the growing expansion of global players in this Players:Key players in this market include Abbott (US), Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd. (Switzerland). These players adopt various strategies, such as product launches, expansions, acquisitions, and collaborations, to excel in this (US)Abbott is a leading player in the HIV diagnostics market, known for its impactful Company Product Portfolio that includes FDA- and CE-approved products. The company's strong Company Market Share in the U.S. is complemented by its strategic focus on expanding its presence in emerging markets through varied Company Positioning strategies. By leveraging inorganic growth strategies, such as collaborations and acquisitions, Abbott aims to bolster its Company Healthineers AG (Germany)Siemens Healthineers is a cornerstone in the HIV diagnostics sphere, providing a broad array of medical solutions. Their focus on organic strategies and innovation has allowed them to maintain a competitive Company Positioning. With a significant presence in Europe, America, and emerging markets, they continue to excel in Company Market Share by offering innovative products that meet health sector Fisher Scientific (US)With a comprehensive Company Product Portfolio that spans PCR-based assays and immunoassays, Thermo Fisher Scientific remains a leader. Their strategies focus on regulatory approvals and strategic acquisitions to enhance their Company Market Share. Through collaboration with healthcare organizations, they aim to boost early HIV detection and improve global health access, effectively securing their Company Positioning and Company Ranking in the Topics Covered: 1 Introduction1.1 Market Definition1.2 Inclusions & Exclusions1.3 Stakeholders2 Executive Summary3 Market Overview3.1 Introduction3.2 Market Dynamics3.2.1 Drivers3.2.1.1 Rising Prevalence of Hiv/Aids3.2.1.2 Increasing Number of Blood Transfusions & Blood Donations3.2.1.3 Advantages Offered by Poc Diagnostic Kits & Instruments3.2.1.4 Increasing Initiatives for Hiv Awareness Campaigns3.2.2 Restraints3.2.2.1 High Cost of Nats3.2.3 Opportunities3.2.3.1 High Growth Potential of Emerging Economies3.2.3.2 Trend of Self-Testing and Growing Preference for At-Home Diagnostic Kits3.2.4 Challenges3.2.4.1 Operational Barriers and Shortage of Skilled Laboratory Technicians3.3 Trends/Disruptions Impacting Customers' Businesses3.4 Value Chain Analysis3.5 Supply Chain Analysis3.6 Ecosystem Analysis3.7 Technology Analysis3.7.1 Key Technologies3.7.1.1 Elisa3.7.2 Complementary Technologies3.7.2.1 Western Blot Tests3.7.3 Adjacent Technologies3.7.3.1 Pcr3.8 Patent Analysis3.9 Key Conferences & Events, 2025-20263.10 Porter's Five Forces Analysis3.10.1 Threat of New Entrants3.10.2 Threat of Substitutes3.10.3 Bargaining Power of Buyers3.10.4 Bargaining Power of Suppliers3.10.5 Intensity of Competitive Rivalry3.11 Impact of Ai/Generative Ai on Hiv Diagnostics Market3.11.1 Market Potential of Ai in Hiv Diagnostics3.11.2 Ai Use Cases3.11.3 Company Implementation of Ai3.11.4 Future of Ai/Generative Ai4 Competitive Landscape4.1 Overview4.2 Key Player Strategies/Right to Win4.2.1 Overview of Strategies Adopted by Key Players in Hiv Diagnostics Market4.3 Revenue Analysis, 2021-20234.4 Market Share Analysis, 20234.4.1 Ranking of Key Market Players4.5 Company Evaluation Matrix: Key Players, 20234.5.1 Stars4.5.2 Emerging Leaders4.5.3 Pervasive Players4.5.4 Participants4.5.5 Company Footprint: Key Players, 20234.5.5.1 Company Footprint4.5.5.2 Region Footprint4.5.5.3 Product Footprint4.5.5.4 End-User Footprint4.6 Company Evaluation Matrix: Startups/Smes, 20234.6.1 Progressive Companies4.6.2 Responsive Companies4.6.3 Dynamic Companies4.6.4 Starting Blocks4.6.5 Competitive Benchmarking: Startups/Smes, 20234.6.5.1 Detailed List of Key Startups/Sme Players4.6.5.2 Competitive Benchmarking of Key Startups/Smes4.7 Company Valuation & Financial Metrics4.8 Brand/Product Comparison4.9 Competitive Scenario4.9.1 Product/Service Launches & Approvals4.9.2 Product Launches & Approvals4.9.3 Deals4.9.4 Expansions4.9.5 Other Developments5 Company Profiles Abbott Siemens Healthineers Grifols, S.A. Danaher Corporation Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. F. Hoffmann-La Roche Ltd. Biomerieux Hologic, Inc. Qiagen Bd Trinity Biotech Orasure Technologies, Inc. Biosynex Sa Wondfo Getein Biotech, Inc. Meril Life Sciences Pvt. Ltd. Accubiotech Co., Ltd. Biolytical Laboratories Inc. Bio Lab Diagnostics (I) Private Limited Alpine Biomedicals Pvt Ltd. Molbio Diagnostics Pvt. Ltd. Fortress Diagnostics Advacare Pharma (Accuquik) Adaltis S.R.L. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
